Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol

Keith C. Bible, Scott A. Boerner, Kathryn Kirkland, Kari L. Anderl, Duane Bartelt, Phyllis A. Svingen, Timothy J. Kottke, Yean K. Lee, Steven Eckdahl, Paul G. Stalboerger, Robert Brian Jenkins, Scott H Kaufmann

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Flavopiridol, the first inhibitor of cyclin-dependent kinases to enter clinical trials, has shown promising antineoplastic activity and is currently undergoing Phase H testing. Little is known about mechanisms of resistance to this agent. In the present study, we have characterized an ovarian carcinoma cell line [OV202 high passage (hp)] that spontaneously developed drug resistance upon prolonged passage in tissue culture. Standard cytogenetic analysis and spectral karyotyping revealed that OV202 hp and the parental low passage line OV202 shared several marker chromosomes, confirming the relatedness of these cell lines. Immunoblotting demonstrated that OV202 and OV202 hp contained similar levels of a variety of polypeptides involved in cell cycle regulation, including cyclin-dependent kinases 2 and 4; cyclins A, D1, and E; and proliferating cell nuclear antigen. Despite these similarities, OV202 hp was resistant to flavopiridol and cisplatin, with increases of 5- and 3-fold, respectively, in the mean drug concentrations required to inhibit colony formation by 90%. In contrast, OV202 hp and OV202 displayed indistinguishable sensitivities to oxaliplatin, paclitaxel, topotecan, 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, doxorubicin, vincristine, and 5-fluorouracil, suggesting that the spontaneously acquired resistance was not attributable to altered P-glycoprotein levels or a general failure to engage the cell death machinery. After incubation with cisplatin, whole cell platinum and platinum-DNA adducts measured using mass spectrometry were lower in OV202 hp cells than OV202 cells. Similarly, after flavopiridol exposure, whole cell flavopiridol concentrations measured by a newly developed high performance liquid chromatography assay were lower in OV202 hp cells. These data are consistent with the hypothesis that acquisition of spontaneous resistance to flavopiridol and cisplatin in OV202 hp cells is due, at least in part, to reduced accumulation of the respective drugs. These observations not only provide the first characterization of a flavopiridol- resistant cell line but also raise the possibility that alterations in drug accumulation might be important in determining sensitivity to this agent.

Original languageEnglish (US)
Pages (from-to)661-670
Number of pages10
JournalClinical Cancer Research
Volume6
Issue number2
StatePublished - Feb 2000

Fingerprint

alvocidib
Cisplatin
Carcinoma
Cell Line
oxaliplatin
Platinum
Spectral Karyotyping
Cyclin-Dependent Kinase 4
Pharmaceutical Preparations
Cyclin-Dependent Kinase 2
Topotecan
Cyclin A
Carmustine
Cyclin E
Cyclin-Dependent Kinases
DNA Adducts
Cytogenetic Analysis
Cyclin D1
Proliferating Cell Nuclear Antigen
P-Glycoprotein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bible, K. C., Boerner, S. A., Kirkland, K., Anderl, K. L., Bartelt, D., Svingen, P. A., ... Kaufmann, S. H. (2000). Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clinical Cancer Research, 6(2), 661-670.

Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. / Bible, Keith C.; Boerner, Scott A.; Kirkland, Kathryn; Anderl, Kari L.; Bartelt, Duane; Svingen, Phyllis A.; Kottke, Timothy J.; Lee, Yean K.; Eckdahl, Steven; Stalboerger, Paul G.; Jenkins, Robert Brian; Kaufmann, Scott H.

In: Clinical Cancer Research, Vol. 6, No. 2, 02.2000, p. 661-670.

Research output: Contribution to journalArticle

Bible, KC, Boerner, SA, Kirkland, K, Anderl, KL, Bartelt, D, Svingen, PA, Kottke, TJ, Lee, YK, Eckdahl, S, Stalboerger, PG, Jenkins, RB & Kaufmann, SH 2000, 'Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol', Clinical Cancer Research, vol. 6, no. 2, pp. 661-670.
Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D, Svingen PA et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clinical Cancer Research. 2000 Feb;6(2):661-670.
Bible, Keith C. ; Boerner, Scott A. ; Kirkland, Kathryn ; Anderl, Kari L. ; Bartelt, Duane ; Svingen, Phyllis A. ; Kottke, Timothy J. ; Lee, Yean K. ; Eckdahl, Steven ; Stalboerger, Paul G. ; Jenkins, Robert Brian ; Kaufmann, Scott H. / Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 2. pp. 661-670.
@article{85febebd789f484fa3e992826a2caeeb,
title = "Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol",
abstract = "Flavopiridol, the first inhibitor of cyclin-dependent kinases to enter clinical trials, has shown promising antineoplastic activity and is currently undergoing Phase H testing. Little is known about mechanisms of resistance to this agent. In the present study, we have characterized an ovarian carcinoma cell line [OV202 high passage (hp)] that spontaneously developed drug resistance upon prolonged passage in tissue culture. Standard cytogenetic analysis and spectral karyotyping revealed that OV202 hp and the parental low passage line OV202 shared several marker chromosomes, confirming the relatedness of these cell lines. Immunoblotting demonstrated that OV202 and OV202 hp contained similar levels of a variety of polypeptides involved in cell cycle regulation, including cyclin-dependent kinases 2 and 4; cyclins A, D1, and E; and proliferating cell nuclear antigen. Despite these similarities, OV202 hp was resistant to flavopiridol and cisplatin, with increases of 5- and 3-fold, respectively, in the mean drug concentrations required to inhibit colony formation by 90{\%}. In contrast, OV202 hp and OV202 displayed indistinguishable sensitivities to oxaliplatin, paclitaxel, topotecan, 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, doxorubicin, vincristine, and 5-fluorouracil, suggesting that the spontaneously acquired resistance was not attributable to altered P-glycoprotein levels or a general failure to engage the cell death machinery. After incubation with cisplatin, whole cell platinum and platinum-DNA adducts measured using mass spectrometry were lower in OV202 hp cells than OV202 cells. Similarly, after flavopiridol exposure, whole cell flavopiridol concentrations measured by a newly developed high performance liquid chromatography assay were lower in OV202 hp cells. These data are consistent with the hypothesis that acquisition of spontaneous resistance to flavopiridol and cisplatin in OV202 hp cells is due, at least in part, to reduced accumulation of the respective drugs. These observations not only provide the first characterization of a flavopiridol- resistant cell line but also raise the possibility that alterations in drug accumulation might be important in determining sensitivity to this agent.",
author = "Bible, {Keith C.} and Boerner, {Scott A.} and Kathryn Kirkland and Anderl, {Kari L.} and Duane Bartelt and Svingen, {Phyllis A.} and Kottke, {Timothy J.} and Lee, {Yean K.} and Steven Eckdahl and Stalboerger, {Paul G.} and Jenkins, {Robert Brian} and Kaufmann, {Scott H}",
year = "2000",
month = "2",
language = "English (US)",
volume = "6",
pages = "661--670",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol

AU - Bible, Keith C.

AU - Boerner, Scott A.

AU - Kirkland, Kathryn

AU - Anderl, Kari L.

AU - Bartelt, Duane

AU - Svingen, Phyllis A.

AU - Kottke, Timothy J.

AU - Lee, Yean K.

AU - Eckdahl, Steven

AU - Stalboerger, Paul G.

AU - Jenkins, Robert Brian

AU - Kaufmann, Scott H

PY - 2000/2

Y1 - 2000/2

N2 - Flavopiridol, the first inhibitor of cyclin-dependent kinases to enter clinical trials, has shown promising antineoplastic activity and is currently undergoing Phase H testing. Little is known about mechanisms of resistance to this agent. In the present study, we have characterized an ovarian carcinoma cell line [OV202 high passage (hp)] that spontaneously developed drug resistance upon prolonged passage in tissue culture. Standard cytogenetic analysis and spectral karyotyping revealed that OV202 hp and the parental low passage line OV202 shared several marker chromosomes, confirming the relatedness of these cell lines. Immunoblotting demonstrated that OV202 and OV202 hp contained similar levels of a variety of polypeptides involved in cell cycle regulation, including cyclin-dependent kinases 2 and 4; cyclins A, D1, and E; and proliferating cell nuclear antigen. Despite these similarities, OV202 hp was resistant to flavopiridol and cisplatin, with increases of 5- and 3-fold, respectively, in the mean drug concentrations required to inhibit colony formation by 90%. In contrast, OV202 hp and OV202 displayed indistinguishable sensitivities to oxaliplatin, paclitaxel, topotecan, 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, doxorubicin, vincristine, and 5-fluorouracil, suggesting that the spontaneously acquired resistance was not attributable to altered P-glycoprotein levels or a general failure to engage the cell death machinery. After incubation with cisplatin, whole cell platinum and platinum-DNA adducts measured using mass spectrometry were lower in OV202 hp cells than OV202 cells. Similarly, after flavopiridol exposure, whole cell flavopiridol concentrations measured by a newly developed high performance liquid chromatography assay were lower in OV202 hp cells. These data are consistent with the hypothesis that acquisition of spontaneous resistance to flavopiridol and cisplatin in OV202 hp cells is due, at least in part, to reduced accumulation of the respective drugs. These observations not only provide the first characterization of a flavopiridol- resistant cell line but also raise the possibility that alterations in drug accumulation might be important in determining sensitivity to this agent.

AB - Flavopiridol, the first inhibitor of cyclin-dependent kinases to enter clinical trials, has shown promising antineoplastic activity and is currently undergoing Phase H testing. Little is known about mechanisms of resistance to this agent. In the present study, we have characterized an ovarian carcinoma cell line [OV202 high passage (hp)] that spontaneously developed drug resistance upon prolonged passage in tissue culture. Standard cytogenetic analysis and spectral karyotyping revealed that OV202 hp and the parental low passage line OV202 shared several marker chromosomes, confirming the relatedness of these cell lines. Immunoblotting demonstrated that OV202 and OV202 hp contained similar levels of a variety of polypeptides involved in cell cycle regulation, including cyclin-dependent kinases 2 and 4; cyclins A, D1, and E; and proliferating cell nuclear antigen. Despite these similarities, OV202 hp was resistant to flavopiridol and cisplatin, with increases of 5- and 3-fold, respectively, in the mean drug concentrations required to inhibit colony formation by 90%. In contrast, OV202 hp and OV202 displayed indistinguishable sensitivities to oxaliplatin, paclitaxel, topotecan, 1,3-bis(2-chloroethyl)-1-nitrosourea, etoposide, doxorubicin, vincristine, and 5-fluorouracil, suggesting that the spontaneously acquired resistance was not attributable to altered P-glycoprotein levels or a general failure to engage the cell death machinery. After incubation with cisplatin, whole cell platinum and platinum-DNA adducts measured using mass spectrometry were lower in OV202 hp cells than OV202 cells. Similarly, after flavopiridol exposure, whole cell flavopiridol concentrations measured by a newly developed high performance liquid chromatography assay were lower in OV202 hp cells. These data are consistent with the hypothesis that acquisition of spontaneous resistance to flavopiridol and cisplatin in OV202 hp cells is due, at least in part, to reduced accumulation of the respective drugs. These observations not only provide the first characterization of a flavopiridol- resistant cell line but also raise the possibility that alterations in drug accumulation might be important in determining sensitivity to this agent.

UR - http://www.scopus.com/inward/record.url?scp=0033974989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033974989&partnerID=8YFLogxK

M3 - Article

C2 - 10690552

AN - SCOPUS:0033974989

VL - 6

SP - 661

EP - 670

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -